Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-X
- Development stage
- Preclinical
- Lead developer
- GeoVax Labs
- Modality
- Vaccines & Immunotherapeutics
01
Overview
MVA-X is a next-generation, single-dose Modified Vaccinia Ankara (MVA)-based vaccine developed by GeoVax in collaboration with Washington State University. It is designed to protect against orthopoxviruses, including mpox (monkeypox virus) and vaccinia virus. The vaccine is engineered to express a peptide-based PD-1 antagonist (specifically the LD10 peptide, an 18-amino-acid peptide derived from the Bacillus thuringiensis Cry1A toxin) directly within the viral genome. This allows for localized, transient checkpoint blockade during early antigen presentation, enhancing CD4+ and CD8+ T-cell responses and providing durable protection with a single dose, matching or exceeding the efficacy of conventional two-dose MVA regimens.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on MVA-X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-X.